Clodron

Quick links to important sections

Clodron

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clodron

Property Description
Active ingredients Clodronic Acid and Lidocaine Hydrochloride
Form Injectable Aqueous Solution
Pharmacological class Bisphosphonate (Bone metabolism regulator) and Local Anesthetic
Common purpose Conservation of bone density and reduction of injection site pain
Origin Synthetic Organic Compound

What Type of Medicine is Clodron and What is its Classification?

Clodron is defined as a Fixed-Dose Combination (FDC) medicinal product, supplied as a sterile injectable aqueous solution intended for intramuscular administration. The product integrates two distinct synthetic organic compounds: the main therapeutic agent, Clodronic Acid (a bisphosphonate), and a pain-alleviating agent, Lidocaine Hydrochloride (a local anesthetic).

Clodronic Acid is classified as a first-generation, non-nitrogenous bisphosphonate. This classification confirms Clodronic Acid's role as one of the earlier drugs developed to regulate natural bone calcification processes, a property clinically recognized in major pharmacological reviews.

Clodron’s Composition and Pharmaceutical Form

The medicine's composition is based on the two principal active substances: Clodronic Acid, present as its disodium salt, and Lidocaine Hydrochloride. This formulation is prepared as a single-use solution for parenteral therapy, which means it is administered via injection, utilizing an aqueous vehicle for delivery. This specific combination, particularly with Lidocaine, represents a differentiated approach to bisphosphonate therapy, as it is designed to enhance patient comfort with the required deep intramuscular administration.

What is the General Purpose of Combining these Two Agents?

The overall purpose is a dual action focused on bone regulation and patient comfort. The Clodronic Acid component works to support the conservation of bone density by binding to bone tissue and slowing down the activity of osteoclasts, which are the cells responsible for excessive bone resorption. The inclusion of the local anesthetic, Lidocaine, serves to provide immediate, localized pain inhibition at the injection site. This addition simplifies the therapy by enhancing patient comfort and improving the overall tolerability of the required intramuscular delivery, a recognized factor in adherence to chronic therapies.

Regulatory References

  1. NIH - Clodronic Acid
  2. WHO Essential Medicines List - Lidocaine

What side effects are possible with Clodron?

Possible Side Effects and Safety Information

Clodron (clodronate disodium) is a bisphosphonate medication and its safety profile is defined by officially documented adverse reactions primarily affecting the gastrointestinal, renal, and musculoskeletal systems.

Adverse Reactions by System and Frequency

Classification System/Organ Class Documented Reactions
Common (1–10%) Gastrointestinal Disorders Diarrhea, nausea, vomiting, abdominal pain.
Rare (<1%) Metabolism and Nutrition Symptomatic hypocalcemia (low blood calcium).
Rare (<1%) Renal and Urinary Disorders Acute renal failure, kidney problems (requiring function monitoring).
Rare/Unknown Musculoskeletal/Connective Osteonecrosis of the jaw (ONJ), atypical femoral fracture, severe bone/joint pain.
Rare (<1%) Immune System Disorders Allergic reactions (e.g., rash, swelling, difficulty breathing).

Clinically Significant and Serious Safety Issues

The most serious, though rare, safety concerns associated with Clodron involve the kidneys and bone structure. Acute renal failure and kidney problems require immediate medical attention and are monitored closely through blood tests, especially in patients with pre-existing renal insufficiency. Long-term use of bisphosphonates is associated with the rare risk of osteonecrosis of the jaw (ONJ) and atypical femoral fractures (spontaneous fracture of the thigh bone).

Contraindications and Safety Restrictions

Clodron is formally restricted (contraindicated) for use in patients with known hypersensitivity to the drug or other bisphosphonates, severe renal functional impairment, or severe inflammation of the gastrointestinal tract. Use during pregnancy and lactation is also restricted due to the potential for harm to the developing baby or infant. Regular monitoring of blood calcium, liver function, and kidney function is explicitly required throughout the course of treatment.

Overdose and Emergency Response

A Clodron (clodronate) overdose can lead to complications primarily related to its effect on calcium levels and the kidneys. As a bisphosphonate, excessive amounts may cause a significant and sustained drop in blood calcium, known as hypocalcaemia.

Potential Overdose Symptoms

Symptoms of a significant overdose may be related to hypocalcaemia and include:

  • Muscle spasms or cramps
  • Tingling or numbness around the mouth, hands, or feet
  • Changes in mental state or confusion
  • Seizures

Since clodronate is eliminated by the kidneys, an overdose can also lead to renal impairment or worsening kidney function. Severe overdoses may also present with stomach pain, vomiting, or an unusual heartbeat.

When to Seek Help

If you suspect an overdose, you must seek emergency medical attention immediately.

  • Call emergency services or poison control right away. Do not wait for symptoms to develop.
  • If symptoms such as severe muscle cramping, seizures, difficulty breathing, or changes in heart rate occur, seek immediate emergency care.

Management of a clodronate overdose typically involves supportive care and correcting the hypocalcaemia, which may include intravenous administration of calcium. It is important to drink plenty of water if you have taken too much clodronate to support kidney function while awaiting medical assistance.

Therapeutic Uses of Clodron

The active ingredient is part of a class of medicines relevant for managing conditions presenting with systemic or localized discomfort related to bone disorders like osteoporosis and Paget's disease. This medication is applied in clinical situations with a high risk of fracture to support the patient during conditions marked by increased physiological stress and the resulting bone loss.

It is also relevant in the therapeutic management of patients with certain cancers, such as multiple myeloma and bone metastases from tumors like breast cancer. It helps address symptom clusters that include bone weakness, associated skeletal pain, and elevated blood calcium levels. The treatment provides support in managing the effects of bone lesions and assists with managing symptoms related to systemic calcium imbalances.

Commonly, this medication is used in conditions presenting with significant symptomatic burden, including chronic bone density loss, oncological bone complications, and pathological bone pain arising from conditions like osteoporotic fractures. The inclusion of the local anesthetic provides a useful benefit. This combination contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities, especially in contexts where managing discomfort is crucial for functional stability.

Quick Fact: Relief for Injection-Site Pain The formulation includes a component that provides localized pain inhibition during the required intramuscular administration, which supports patient comfort.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Clodron

Clodron (Clodronic Acid) eligibility is defined by official regulatory documents, which establish clear restrictions based on patient profile and organ function. The medication is authorized primarily for use in adult patients and the elderly; its safety and efficacy have not been established in the pediatric population.

Use is absolutely contraindicated (prohibited) for specific patient groups:

  • Patients with a known hypersensitivity to Clodronate Disodium or other bisphosphonates.
  • Patients receiving concomitant treatment with other bisphosphonates.
  • Patients with severe renal impairment, typically defined as a Creatinine Clearance below 10 mL/min or serum creatinine exceeding 440 mu mol/L.
  • Patients in the state of pregnancy or lactation (breastfeeding).

Condition-specific eligibility rules mandate that patients with moderate renal impairment (CrCl 10 -30 mL/min) are only eligible for use with a regulatory-mandated dose reduction. Additionally, pre-existing hypocalcemia must be corrected prior to initiating treatment to ensure eligibility is met. For patients with hepatic impairment, no specific dosage adjustment is typically required, though monitoring is standard regulatory practice.

What should I know about interactions with other medicines?

Clodron Interactions with other medicines and products

The officially documented interaction profile for Clodron, a fixed-dose combination of Clodronic Acid and Lidocaine Hydrochloride, is defined by both pharmacodynamic and pharmacokinetic effects, as stated in government regulatory documents.

Interaction scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Bisphosphonates, Aminoglycosides, Loop Diuretics, CYP1A2 and CYP3A4 Inhibitors, Beta-Adrenergic Blockers, Nephrotoxic Drugs.
Specific interacting medicines (if explicitly listed) Estramustine Phosphate, Cimetidine, Fluvoxamine, Propranolol.
Mechanistic basis of interactions Additive Pharmacodynamic Effect (e.g., increased risk of hypocalcemia); Clearance Reduction (e.g., reduced Lidocaine clearance via decreased hepatic blood flow or CYP inhibition); Complex Formation (Clodronic Acid chelation by multivalent cations).
Timing-based interaction rules For the oral form of Clodronic Acid, separation from multivalent cation-containing substances (e.g., food, antacids, mineral supplements) is required to prevent impaired absorption.
Population-specific interaction notes Hepatic Impairment: Lidocaine clearance is decreased, potentially leading to increased systemic exposure. Nephrotoxic Drugs: Increased risk or severity of nephrotoxicity and hypocalcemia when combined with Clodronic Acid.
Interaction-related restrictions Concomitant use with other bisphosphonates is formally documented as contraindicated.

Official interaction statements

  • Concomitant use with other bisphosphonates is formally documented as contraindicated due to the risk of additive adverse effects.
  • Aminoglycosides or Loop Diuretics co-administered with Clodronic Acid may result in an additive effect to lower serum calcium.
  • CYP1A2 and/or CYP3A4 Inhibitors (e.g., Fluvoxamine, Cimetidine) have the potential to increase Lidocaine plasma levels by decreasing its clearance, requiring official monitoring.
  • Beta-Adrenergic Blockers (e.g., Propranolol) are documented to increase Lidocaine plasma levels by reducing hepatic blood flow.
  • Administration of Clodronic Acid with Estramustine Phosphate is reported to increase the serum concentration of Estramustine Phosphate.

Connection to the overall interaction profile The regulatory documents define the product’s interaction structure based on the additive pharmacodynamic risks of the bisphosphonate component with agents affecting calcium homeostasis and the pharmacokinetic interactions of the local anesthetic component with substances that modify its hepatic clearance. This dual-component structure includes prohibited combinations and use-with-caution constraints related to exposure modification and additive effects on organ systems.

Mechanism of Action

Cellular Mechanism: Targeted Osteoclast Apoptosis

Clodronic Acid binds directly to bone mineral and is internalized by osteoclasts (bone-resorbing cells). Inside the cell, the drug is metabolized into a cytotoxic compound that inhibits the mitochondrial ADP/ATP translocase enzyme, disrupting the cell's essential energy transfer and inducing programmed cell death. This process leads to the core physiological consequence of reducing the rate of bone mineral removal (bone resorption).

Local Mechanism: Peripheral Nerve Signal Blockade

Lidocaine Hydrochloride exerts its effect by acting as an ion channel blocker. It binds to the inner part of Voltage-Gated Sodium Channels ( Na^+ channels) within the peripheral nerve membranes, physically preventing the necessary rapid influx of sodium ions. This molecular blockade stabilizes the nerve membrane and inhibits the conduction of electrical impulses, resulting in the physiological effect of immediate, localized inhibition of action potential propagation in sensory nerves.

Mechanistic Synergy and Pathway Coordination

This is a fixed-dose combination leveraging two distinct mechanisms for functional coordination: Clodronic Acid provides the long-term, systemic modulation of bone cell activity, while Lidocaine ensures rapid, peripheral inhibition of nociceptive signal conduction. The combined mechanism coordinates the local interruption of peripheral neural excitability with the systemic bone cell modulation.

Dosage and Administration Information

Clodron (Clodronic Acid) is an anti-resorptive agent available in various forms, and its administration follows established instructions to ensure correct intake.

Official Administration Guidelines

Administration Route Standard Adult Dosing (Regulatory Range) Frequency and Timing
Oral (Capsule/Tablet) 1600 mg to 2400 mg daily; maximum 3200 mg daily. Once daily or in two equally divided doses.
Intravenous (IV) Infusion 300 mg daily, or a single 1500 mg dose. Daily for up to 7 consecutive days (multiple dose regimen).
Intramuscular (IM) Injection 100 mg or 200 mg per injection. Intermittent, often administered weekly or bi-weekly.

Key Procedural Requirements

Oral Intake Conditions: To ensure adequate absorption, oral forms must be swallowed whole with plain water on an empty stomach. Instructions require that the dose is taken at least one hour before or two hours after food, and it must not be consumed with milk or other calcium-containing products. Following administration, the patient must remain in an upright position for at least 30 minutes.

Intravenous (IV) Administration: The IV concentrate requires mandatory dilution in specific calcium-free solutions (e.g., 0.9% Sodium Chloride or 5% Dextrose) before use. The resulting solution must be delivered only as a slow intravenous infusion, lasting a minimum of two hours (or four hours for the 1500 mg single dose) to comply with safety parameters. The IV route is typically limited to a maximum of seven consecutive days in the acute setting.

Population Adjustments: Dosage adjustment is required for patients with impaired renal function (Creatinine Clearance <50 mL/min), with specific dose reductions. No specific adjustment is typically required for the elderly, though use is not established in pediatric populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clodron

This section describes the types of clinical studies and research that have monitored the use of Clodronic Acid, the main active ingredient in Clodron, in the conditions for which it was studied for. The research described here focuses on group patterns observed in trials and contributes to the broader evidence landscape. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.


Evidence for Oncological Bone Management

Research was studied for its application in conditions related to bone damage from cancer, such as multiple myeloma and bone metastases. These trials, frequently conducted as Randomized Controlled Trials (RCTs), and their subsequent meta-analyses, research examined a set of specific clinical and physical outcomes. The primary focus was on measuring the incidence of Skeletal-Related Events (SREs), and studies also monitored outcomes related to physical discomfort.

What the studies reported:

  • Studies monitored the frequency of SREs occurring in the observed populations as an outcome, tracking differences versus control groups.
  • Outcomes related to overall survival were also monitored; however, evidence is limited because findings were mixed across various studies and subgroups.

Evidence for Chronic Bone Density Support

Clodronic Acid was evaluated in studies related to bone loss, including postmenopausal osteoporosis. Research primarily involved Controlled Clinical Trials where research examined changes in Bone Mineral Density (BMD) at the hip and spine. The trials also explored outcomes related to systemic or functional imbalance by tracking the occurrence of new vertebral and non-vertebral fractures.

What the studies reported:

  • Studies reported measurements of BMD and described how bone density at the spine and hip evolved in the observed populations over the study periods.
  • Trials monitored the rate of new fractures observed in the study population, tracking differences versus control groups.

Research Gaps and Areas of Uncertainty

This research highlights what is known — and what is still uncertain. The certainty of the evidence can vary across different outcomes and indications.

  • Comparative evidence is lacking in large, recent trials directly comparing Clodronic Acid to newer bisphosphonates now commonly used in medicine.
  • Evidence quality varies across studies, particularly in older trials where sample sizes were modest or the control groups did not reflect current standards of care.
  • Long-term effects are not fully established beyond the initial controlled study periods; evidence is still limited for long-term maintenance outcomes.

Frequently Asked Questions (FAQ)

Common questions about Clodron (FAQ)


Q: Is Clodron a type of steroid?

Clodron's main active ingredient, Clodronic Acid, is officially classified as a bisphosphonate. This means it is a type of medicine that helps regulate bone metabolism. Bisphosphonates are chemically and functionally distinct from steroids, which are not mentioned in the regulatory classification for this drug.


Q: Can I take Clodron if I am taking over-the-counter pain relievers?

The official documentation cautions that there have been reports of acute renal (kidney) failure when Clodronate Disodium was used at the same time as certain non-steroidal anti-inflammatory drugs (NSAIDs). Regulatory warnings indicate that if these medicines are used together, close monitoring may be required.


Q: Can Clodron interact with herbal supplements?

Official patient counseling materials generally advise individuals to inform their healthcare providers about all concurrent medications, including any herbal drugs or supplements. Official patient materials highlight the importance of discussing all products with a healthcare professional as potential interactions are not always defined.


Q: Does Clodron have a Black Box Warning in the US?

The DailyMed labeling for Clodronate Disodium in the United States does not currently contain a Black Box Warning. However, the official documentation includes specific regulatory warnings concerning rare but serious safety issues, such as osteonecrosis of the jaw and atypical femoral fractures.


Q: Can Clodron cause changes in appetite?

Official regulatory-sourced patient information for the drug lists decreased appetite as a potential side effect. Other common gastrointestinal side effects reported include nausea, vomiting, and abdominal discomfort.


Q: Why do some official drug documents list so many potential side effects?

Official drug documents are required by regulatory bodies to list every potential side effect reported in clinical trials and during post-marketing surveillance. This regulatory practice contributes to comprehensive disclosure. The mere listing of an event does not guarantee it will occur, as many are reported infrequently or are classified as rare.


Q: How quickly does Clodron start to affect the body?

According to official pharmacokinetic data, the drug is quickly absorbed after oral intake, reaching peak plasma concentration in about 0.5 to 1 hour. The drug then binds to the bone, where it performs its long-term action by slowing down bone resorption.


Q: Is Clodron similar to other medicines like X or Y?

Clodron's active ingredient is classified as a first-generation bisphosphonate. This means it belongs to a family of drugs that includes agents such as alendronic acid. It is related to these other bisphosphonates in terms of its chemical structure and general regulatory function in bone metabolism.


Q: Can Clodron cause weight gain?

Weight gain is not explicitly listed as a common or rare adverse reaction in the official documentation provided by regulatory sources. However, side effects related to fluid retention, which can sometimes be linked to weight change, are listed as a rare potential adverse event.


Q: Does Clodron affect my ability to drive or operate machines?

Formal studies on the drug's effect on driving have not been officially performed. If side effects that could potentially impair judgment are experienced, such as dizziness or mood or mental changes (listed as rare adverse events), the ability to drive or operate machinery may be affected.


Q: Is it normal to feel tired when starting Clodron?

Official documentation notes that unusual tiredness or weakness is listed as a rare potential side effect. This type of fatigue is also mentioned as a symptom that could occur in the event of an overdose.


Q: Does Clodron cure the condition, or just manage the symptoms?

Official patient information states clearly that Clodron is designed as a treatment to control the underlying condition, but it does not cure it. It is primarily a management therapy focused on slowing down processes like bone resorption.


Q: How long does the effect of one dose of Clodron typically last?

The drug binds strongly to bone tissue after administration and is released slowly over time. Because of this, the clinical effect of Clodron on bone is considered long-lasting, extending beyond the relatively short plasma half-life of the active ingredient.


Q: Can Clodron affect my blood pressure?

While not a common side effect, the possibility of high blood pressure (hypertension) has been reported as an adverse reaction in clinical trials involving related bisphosphonate medicines in the same drug class.


Q: How is Clodron different from a placebo in clinical trials?

In clinical trials, Clodron demonstrated measurable effects that differentiated it from a placebo, such as a reduction in skeletal-related events (SREs) and documented changes in Bone Mineral Density (BMD). A placebo is an inactive substance and does not produce a biological effect.


Q: Do I need special tests before starting Clodron?

Official guidelines indicate that blood work, particularly for kidney function and calcium levels, may be checked prior to initiating treatment. Additionally, specific assessments, such as dental exams, may be utilized to help ensure pre-existing hypocalcemia (low blood calcium) is addressed.


Q: What is the general long-term safety profile of Clodron?

The safety profile for long-term use includes the risk of serious, though rare, conditions such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures. Regulatory documents note that data beyond the initial controlled study periods are often limited, though these rare risks are highlighted in the context of chronic therapy.


Q: What is the purpose of Clodron's active ingredient?

Clodron is a combination drug with two active components, each serving a distinct purpose. Clodronic Acid helps regulate bone activity to support bone density, while Lidocaine Hydrochloride is included to provide local pain relief at the site of the injection.


Q: Is Clodron generally a short-term or long-term treatment?

The recommended duration depends on the form of administration. The intravenous (IV) route, used for acute settings, is typically short-term, limited to a maximum of seven consecutive days. However, oral therapy is generally prescribed as a long-term daily or twice-daily maintenance treatment.


Q: What evidence exists for Clodron's use in children?

Official regulatory documents explicitly state that the safety and effectiveness of Clodron have not been established in children. For this reason, the medicine is primarily authorized for use in adult patients and the elderly.


Q: Can Clodron affect my mood or cause depression?

The list of adverse events in official documentation includes mood or mental changes as a rare potential side effect. This potential reaction is also noted as a symptom that can occur in the event of an overdose.


Q: Is there a generic version of Clodron available?

The main active ingredient, Clodronic Acid, is classified as an older bisphosphonate and is now available in many regions as a generic medicine under various trade names.


Q: If I miss a dose of Clodron, what should I generally do?

Regulatory-derived patient guidance usually describes skipping a missed oral dose and continuing with the next scheduled dose at the usual time. The guidance cautions against taking two doses at the same time to avoid increasing the risk of side effects.


Q: Are there specific times of day when Clodron is usually taken?

Official guidance often indicates that for once-daily dosing, the dose is preferably taken in the morning. This timing is primarily to maximize the separation between the dose and food or other medicines, which is necessary for proper absorption.


Q: Does alcohol make the side effects of Clodron worse?

Official patient information indicates that the use of alcohol during treatment should be discussed with a healthcare professional. This is because alcohol or tobacco may potentially cause interactions, although specific details on worsening side effects are not explicitly defined in the regulatory label.


Q: Is there a maximum time a person is generally allowed to use Clodron?

For the intravenous (IV) route, treatment is officially limited to a maximum of seven consecutive days in the acute setting. For oral administration, there is no single mandated time limit, and the duration of long-term use is determined by the specific condition and treatment plan.


Q: Can Clodron be split or crushed?

Official guidance for the oral tablet form states that the tablets should generally be swallowed whole with water. While some regulatory guidance permits breaking a tablet in half for easier swallowing, the full dose is intended to be taken at once, and tablets are generally not crushed or dissolved.


Q: How often do the serious side effects of Clodron occur in patients?

The most serious side effects, such as acute renal failure, osteonecrosis of the jaw, and atypical femoral fracture, are officially classified as rare or having an unknown frequency in the regulatory product labeling. Rare means they occur in less than 1% of the population observed in clinical trials.


Q: Is Clodron used in veterinary medicine?

Yes, regulatory information indicates that a specific formulation of Clodronate Disodium is restricted by the FDA for use by a licensed veterinarian. This is for the control of clinical signs associated with navicular syndrome in horses.


Q: Does Clodron require a prescription everywhere in the world?

In the United States, Clodronate Disodium is classified as a prescription drug (Rx Only) for human use. This means it is generally not available for purchase over the counter.


Q: Can Clodron cause skin reactions or rashes?

Official documentation notes that skin reactions such as rashes are listed as part of the possible allergic reactions. These allergic events, which can also include swelling and difficulty breathing, are documented as rare side effects.


Q: Do specific health conditions make Clodron less effective?

Official regulatory documents emphasize that poor oral absorption is a major factor affecting the drug's effectiveness. Conditions leading to poor adherence to the required empty-stomach intake rules may therefore result in reduced systemic exposure and efficacy.


Q: What is the typical age range of patients who use Clodron?

The medicine is primarily authorized for use in adult patients and the elderly. Clinical studies have involved patients across the adult lifespan, including those over 65 years of age.

How should Clodron be stored and disposed of?

How to Store and Dispose of Clodron?

This section outlines the official, labeled requirements for the storage and disposal of the Clodron injectable solution, as defined by governmental regulatory sources.

Storage Condition Official Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F); keep from freezing and excessive heat.
Protection Must be stored in its original container and protected from light.
Container Rule As a single-dose product, any unused portion must be discarded immediately after initial use.
Safety Keep out of the reach of children.

Official Disposal Guidelines

Disposal of Unused Medicine: Unwanted or expired Clodron should be disposed of by following official take-back program instructions. If a take-back program is unavailable, the alternative is to mix the medicine with an undesirable substance (such as dirt or coffee grounds) in a sealed container and place it in the household trash. Do not flush the medicine down the toilet or sink, as this is not an officially recommended method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clodron found in:

A-Z Index: